These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19269199)

  • 21. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
    Heidenreich A; Thüer D; Polyakov S
    Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
    Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
    J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
    Ehrlich Y; Yossepowitch O; Kedar D; Baniel J
    BJU Int; 2006 Jun; 97(6):1221-4. PubMed ID: 16686715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
    Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
    Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
    Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
    J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
    Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
    Steiner H; Peschel R; Bartsch G
    BJU Int; 2008 Aug; 102(3):310-4. PubMed ID: 18325053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings.
    Brown JA; Bihrle R; Foster RS
    Urology; 2008 May; 71(5):911-4. PubMed ID: 18342916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
    Heidenreich A; Pfister D; Witthuhn R; Thüer D; Albers P
    Eur Urol; 2009 Jan; 55(1):217-24. PubMed ID: 18926622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
    Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
    Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
    Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
    Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
    Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
    Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
    Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of retroperitoneal lymphadenectomy in mature teratoma of the testis.
    Heidenreich A; Moul JW; McLeod DG; Mostofi FK; Engelmann UH
    J Urol; 1997 Jan; 157(1):160-3. PubMed ID: 8976241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours.
    Steiner H; Müller T; Gozzi C; Akkad T; Bartsch G; Berger AP
    BJU Int; 2006 Aug; 98(2):349-52. PubMed ID: 16626306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Urologic treatment of testicular germ cell cancer].
    Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
    Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
    Beck SD; Patel MI; Sheinfeld J
    J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.